Related Experiment Videos
Andrenocortical carcinomas: twelve-year prospective experience
Libuse Tauchmanovà1, Annamaria Colao, Luigi Antonio Marzano
1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy. tauchman@unina.it
World Journal of Surgery
|December 14, 2004
Summary
Curative surgery offers the best survival for adrenocortical carcinoma (AC). Early detection through monitoring blood pressure and hormone levels aids in identifying recurrences of this rare cancer.
Area of Science:
- Endocrinology
- Oncology
- Surgical Oncology
Background:
- Adrenocortical carcinoma (AC) is a rare endocrine tumor with a generally poor prognosis.
- Limited data exists on prognostic factors and optimal management strategies for AC.
Purpose of the Study:
- To evaluate prognostic factors and treatment outcomes in patients with adrenocortical carcinoma.
- To identify predictors of recurrence and survival in AC.
Main Methods:
- Prospective evaluation of 22 patients with adrenocortical carcinoma (AC) at a single center.
- Analysis of tumor stage, surgical approach, clinical presentation, and treatment response.
- Correlation of histopathological features with prognosis and survival outcomes.
Main Results:
- Curative surgery significantly improved survival compared to debulking or no surgery (p < 0.0001).
- High mitotic rate and undifferentiated cellular pattern were associated with worse prognosis.
- Early treatment response to mitotane chemotherapy was observed in patients treated sooner after initial surgery.
- Hypertension was a common clinical finding, often linked to cardiovascular risk factors.
Conclusions:
- Curative surgery is the most effective treatment for adrenocortical carcinoma.
- Monitoring blood pressure, endocrine, and metabolic parameters is crucial for early detection of AC recurrence.
- Recurrent AC demonstrates increasing aggressiveness and shorter intervals between relapses.